scholarly journals Family history of cancer and risk of pediatric and adolescent Hodgkin lymphoma: A Children's Oncology Group study

2015 ◽  
Vol 137 (9) ◽  
pp. 2163-2174 ◽  
Author(s):  
Amy M. Linabery ◽  
Erik B. Erhardt ◽  
Michaela R. Richardson ◽  
Richard F. Ambinder ◽  
Debra L. Friedman ◽  
...  
Keyword(s):  
Family History ◽  
Hodgkin Lymphoma ◽  
Oncology Group ◽  
Oncology Group Study ◽  
Family History Of Cancer ◽  
History Of ◽  
History Of Cancer

Abstract 1296: Family history of cancer and rhabdomyosarcoma in children: a report from the Children's Oncology Group

2014 ◽  
Author(s):  
Philip J. Lupo ◽  
Heather E. Danysh ◽  
Sharon E. Plon ◽  
David Malkin ◽  
Simone Hettmer ◽  
...  
Keyword(s):  
Family History ◽  
Oncology Group ◽  
Family History Of Cancer ◽  
History Of ◽  
History Of Cancer

Increased Risk Of Brain Tumors Among First-Degree Relatives Of Patients With Therapy-Related Myelodysplasia and Acute Myeloid Leukemia (t-MDS/AML)

Blood ◽  
2013 ◽  
Vol 122 (21) ◽  
pp. 5228-5228
Author(s):  
Patrick Halliday ◽  
Alysia Bosworth ◽  
Can-Lan Sun ◽  
Tongjun Kang ◽  
Lindsey Hageman ◽  
...  
Keyword(s):  
Family History ◽  
Brain Tumors ◽  
Hodgkin Lymphoma ◽  
Positive Family History ◽  
Individual Variability ◽  
Excess Risk ◽  
Family History Of Cancer ◽  
First Degree Relatives ◽  
History Of ◽  
History Of Cancer

Abstract Background t-MDS/AML is a leading cause of non-relapse mortality among patients undergoing autologous hematopoietic cell transplantation (aHCT) for Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). A combination of therapeutic exposures prior to aHCT, aHCT-related conditioning regimens, peripheral blood stem cell mobilization and post-aHCT hematopoietic regeneration contribute to the development of t-MDS/AML. However, significant inter-individual variability is observed despite similar therapeutic exposures. This inter-individual variability could possibly be explained by low-penetrance, high-prevalence polymorphisms in genes involved in DNA damage and repair. On the other hand, a small but quantifiable fraction of the inter-individual variability observed in the risk of t-MDS/AML (in the context of comparable genotoxic exposures) could be attributable to the familial predisposition to cancer that is associated with rare polymorphisms in high-penetrance genes – an area that has not been explored thus far. Methods This study aimed to describe the excess risk of specific cancers among first-degree relatives of HL/NHL patients with t-MDS/AML after aHCT compared to first-degree relatives of HL/NHL patients without t-MDS/AML. We have constructed a prospective, longitudinal cohort of patients undergoing aHCT for HL and NHL, where patients are followed from pre-aHCT to 10 yrs post-aHCT (period of risk for t-MDS/AML) allowing for complete ascertainment of t-MDS/AML cases. Study participants were invited to complete a family history questionnaire. Probands with at least one sibling, parent or offspring with cancer were defined as having a positive family history of cancer. Person-yrs at risk for the cohort of relatives were determined from birth to the development of cancer, death or date of questionnaire completion (whichever occurred first). Person-yrs at risk were stratified by age, sex and calendar yr and applied to SEER registry data to yield expected numbers of each type of cancer to compute standardized incidence ratios (SIR: observed/expected) with 95% confidence intervals (CI) for cancer incidence in first-degree relatives of probands with and without t-MDS/AML. Results The 446 HL/NHL patients in the cohort reported on 2,664 first-degree relatives, yielding 130,578 person-yrs of follow up. A positive family history of cancer was reported by 103 patients, with 370 incidences of cancer. When stratified by t-MDS/AML status, a positive family history of cancer was identified in 15 of 64 patients with t-MDS/AML (23%) vs. 88 of 382 (23%) patients without t-MDS/AML, yielding an overall SIR of 1.09 (0.82-1.42) for relatives of HL/NHL patients with t-MDS/AML vs. 1.01 (0.89-1.13) for relatives of HL/NHL patients without t-MDS/AML (p=0.60) (Table). However, examination of risk by family history of specific cancer type demonstrated an excess risk of brain tumors among relatives of HL/NHL patients with t-MDS/AML (SIR=5.27, 95% CI, 1.89-11.31) as opposed to relatives of lymphoma patients without t-MDS/AML (SIR=1.55, 95% CI, 0.71-2.89, p=0.03) (Table). This excess risk was contributed to largely by brain tumors among fathers of patients with t-MDS/AML (SIR=5.84, 95% CI, 0.97-18.05) when compared with fathers of patients without t-MDS/AML (SIR=1.05, 95% CI, 0.18-3.27, p=0.09). Conclusions This study demonstrates an excess risk of brain tumors among first-degree relatives (and in particular fathers) of HL/NHL patients with t-MDS/AML after aHCT, as compared to HL/NHL patients without t-MDS/AML. This information may serve as a basis for the discovery of underlying genetic predisposition syndromes as well as specific genes responsible for their development. Disclosures: No relevant conflicts of interest to declare.

scholarly journals Family history of cancer and malignant germ cell tumors in children: A report from the Children’s Oncology Group

2009 ◽  
Vol 21 (2) ◽  
pp. 181-189 ◽  
Author(s):  
Jenny N. Poynter ◽  
Amy H. Radzom ◽  
Logan G. Spector ◽  
Susan Puumala ◽  
Leslie L. Robison ◽  
...  
Keyword(s):  
Family History ◽  
Germ Cell ◽  
Germ Cell Tumors ◽  
Oncology Group ◽  
Family History Of Cancer ◽  
History Of ◽  
Malignant Germ Cell Tumors ◽  
History Of Cancer

scholarly journals Family history of cancer in children and adolescents with germ cell tumours: a report from the Children’s Oncology Group

2017 ◽  
Vol 118 (1) ◽  
pp. 121-126 ◽  
Author(s):  
Jenny N Poynter ◽  
Michaela Richardson ◽  
Michelle Roesler ◽  
Mark Krailo ◽  
James F Amatruda ◽  
...  
Keyword(s):  
Family History ◽  
Germ Cell ◽  
Children And Adolescents ◽  
Germ Cell Tumours ◽  
Oncology Group ◽  
Family History Of Cancer ◽  
History Of ◽  
Cancer In Children ◽  
History Of Cancer

scholarly journals Family history of cancer and childhood rhabdomyosarcoma: a report from the Children's Oncology Group and the Utah Population Database

2015 ◽  
Vol 4 (5) ◽  
pp. 781-790 ◽  
Author(s):  
Philip J. Lupo ◽  
Heather E. Danysh ◽  
Sharon E. Plon ◽  
Karen Curtin ◽  
David Malkin ◽  
...  
Keyword(s):  
Family History ◽  
Oncology Group ◽  
Population Database ◽  
Family History Of Cancer ◽  
History Of ◽  
Childhood Rhabdomyosarcoma ◽  
History Of Cancer

scholarly journals Risk of Second Cancer in Hodgkin Lymphoma Survivors and Influence of Family History

2017 ◽  
Vol 35 (14) ◽  
pp. 1584-1590 ◽  
Author(s):  
Amit Sud ◽  
Hauke Thomsen ◽  
Kristina Sundquist ◽  
Richard S. Houlston ◽  
Kari Hemminki
Keyword(s):  
Family History ◽  
Hodgkin Lymphoma ◽  
Cumulative Incidence ◽  
Second Cancer ◽  
Second Cancers ◽  
Family History Of Cancer ◽  
Significant Difference ◽  
History Of ◽  
The Impact ◽  
History Of Cancer

Purpose Although advances in Hodgkin lymphoma (HL) treatment have led to improved disease-free survival, this has been accompanied by an increased risk of second cancers. We sought to quantify the second cancer risks and to investigate the impact of family history. Patients and Methods Using the Swedish Family-Cancer Project Database, we identified 9,522 individuals with primary HL diagnosed between 1965 and 2012. We calculated standardized incidence ratios and cumulative incidence of second cancer in HL survivors and compared the standardized incidence ratios of lung, breast, colorectal, and all second cancers in HL survivors with and without a site-specific family history of cancer. Interactions between family history of cancer and HL treatment were evaluated under additive and multiplicative models. Results Overall, the risk of a second cancer in HL survivors was increased 2.39-fold (95% CI, 2.29 to 2.53). The 30-year cumulative incidence of breast cancer in women diagnosed with HL at younger than 35 years of age was 13.8%. We observed no significant difference in cancer risk over successive time periods. The risk of all second cancers was 1.3-fold higher for HL survivors with a first-degree relative with cancer ( P < .001), with 3.3-fold, 2.1-fold, and 1.8-fold differences shown for lung, colorectal, and breast cancers, respectively. Moreover, a greater than additive interaction between family history of lung cancer and HL treatment was shown ( P = .03). Conclusion HL survivorship is associated with a substantive risk of a second cancer. Notably, the risk is higher in individuals with a family history of cancer. This information should be used to inform risk-adapted therapy and to assist in screening to reduce long-term morbidity and mortality in patients with HL.

scholarly journals Family history of cancer in first degree relatives and risk of cancer of unknown primary

2021 ◽  
Author(s):  
Alexander L. R. Grewcock ◽  
Karlijn E. P. E. Hermans ◽  
Matty P. Weijenberg ◽  
Piet A. Brandt ◽  
Caroline Loef ◽  
...  
Keyword(s):  
Family History ◽  
Cancer Of Unknown Primary ◽  
Unknown Primary ◽  
Family History Of Cancer ◽  
First Degree Relatives ◽  
History Of ◽  
Risk Of Cancer ◽  
History Of Cancer

scholarly journals Clinical, Pathological and Molecular Characteristics of Chilean Patients with Early-, Intermediate- and Late-Onset Colorectal Cancer

Cells ◽  
2021 ◽  
Vol 10 (3) ◽  
pp. 631
Author(s):  
Karin Alvarez ◽  
Alessandra Cassana ◽  
Marjorie De La Fuente ◽  
Tamara Canales ◽  
Mario Abedrapo ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Family History ◽  
Age Of Onset ◽  
Late Onset ◽  
Molecular Characteristics ◽  
Family History Of Cancer ◽  
Molecular Features ◽  
Age Of Diagnosis ◽  
History Of ◽  
History Of Cancer

Colorectal cancer (CRC) is the second most frequent neoplasm in Chile and its mortality rate is rising in all ages. However, studies characterizing CRC according to the age of onset are still lacking. This study aimed to identify clinical, pathological, and molecular features of CRC in Chilean patients according to the age of diagnosis: early- (≤50 years; EOCRC), intermediate- (51–69 years; IOCRC), and late-onset (≥70 years; LOCRC). The study included 426 CRC patients from Clinica Las Condes, between 2007 and 2019. A chi-square test was applied to explore associations between age of onset and clinicopathological characteristics. Body Mass Index (BMI) differences according to age of diagnosis was evaluated through t-test. Overall (OS) and cancer-specific survival (CSS) were estimated by the Kaplan–Meier method. We found significant differences between the age of onset, and gender, BMI, family history of cancer, TNM Classification of Malignant Tumors stage, OS, and CSS. EOCRC category was characterized by a family history of cancer, left-sided tumors with a more advanced stage of the disease but better survival at 10 years, and lower microsatellite instability (MSI), with predominant germline mutations. IOCRC has shown clinical similarities with the EOCRC and molecular similarities to the LOCRC, which agrees with other reports.

Sign in / Sign up

Export Citation Format

Share Document